<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984721</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/16/8768</org_study_id>
    <nct_id>NCT03984721</nct_id>
  </id_info>
  <brief_title>Amyloidosis Typing Using Mass Spectrometry-based Proteomics: a New Accurate Tool for Difficult Typing</brief_title>
  <acronym>TYPAMYL</acronym>
  <official_title>Amyloidosis Typing Using Mass Spectrometry-based Proteomics: a New Accurate Tool for Difficult Typing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Proteomics and Mass Spectrometry of Biomolecules, Proteomics Infrastructure of Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to establish that a new technique of amyloidosis typing by Proteomics
      (based on nanoLC-MS/MS mass spectrometry) allows typing in &gt; 90% of observations in patients
      whose Amyloidosis is reported to have failed typing (impossible typing, uncertain or
      inconsistent) with the traditional anatomopathological approach, and this in a cohort of 40
      patients identified consecutively in the Department of pathological anatomy and cytology of
      the University Hospital of Toulouse and included prospectively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Inclusion of 40 patients identified by the Department of Anatomy and pathological cytology at the University of Toulouse.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amyloidosis typing</measure>
    <time_frame>Day 0</time_frame>
    <description>Amyloidosis typing rate with the new technique</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to return the result</measure>
    <time_frame>Day 0</time_frame>
    <description>Time to return the result with the new technique (time in days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance</measure>
    <time_frame>Day 0</time_frame>
    <description>Agreement between the proteomic conclusion and the clinical judgement (binary answer : yes/no)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Amylose typing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amyloidosis typing by nanoLC-MS/MS in patients diagnosed with Amyloidosis but unable to be typed</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Amyloidosis typing using mass spectrometry-based proteomics</intervention_name>
    <description>Amyloidosis typing using nanoLC-MS/MS method</description>
    <arm_group_label>Amylose typing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Amyloidosis by Red Congo staining and birefringence in polarized light on
             tissue sampling

          -  Immunolabeling Amyloidosis typing

               1. impossible (no frozen sample available)

               2. or inconclusive (doubtful)

               3. or inconsistent with clinical, biological, genetic and iconographic data

          -  Signature of the informed consent form

        Exclusion Criteria:

          -  Insufficient tissue material to perform the new technique

          -  Person placed under judicial protection

          -  Pregnant and breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique CHAUVEAU</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rangueil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magalie COLOMBAT</last_name>
    <phone>33-531156140</phone>
    <email>Colombat.Magali@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magalie COLOMBAT</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Magalie COLOMBAT</last_name>
      <email>Colombat.Magali@iuct-oncopole.fr</email>
    </contact>
    <contact_backup>
      <last_name>Dominique CHAUVEAU</last_name>
      <email>chauveau.d@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Dominique CHAUVEAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanislas FAGUER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine HUART</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David RIBES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascal CINTAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier LAIREZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent SAILLER</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood. 2009 Dec 3;114(24):4957-9. doi: 10.1182/blood-2009-07-230722. Epub 2009 Oct 1.</citation>
    <PMID>19797517</PMID>
  </reference>
  <reference>
    <citation>Theis JD, Dasari S, Vrana JA, Kurtin PJ, Dogan A. Shotgun-proteomics-based clinical testing for diagnosis and classification of amyloidosis. J Mass Spectrom. 2013 Oct;48(10):1067-77. doi: 10.1002/jms.3264.</citation>
    <PMID>24130009</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mass spectrometry based proteomic analysis</keyword>
  <keyword>NanoLC-MS/MS</keyword>
  <keyword>Amyloidosis typing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

